These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23179009)

  • 1. Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study.
    Dischereit G; Tarner IH; Müller-Ladner U; Lange U
    Clin Rheumatol; 2013 Mar; 32(3):377-81. PubMed ID: 23179009
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab has no apparent effect in the inner ear hearing function of patients with rheumatoid arthritis and ankylosing spondylitis.
    Toktas H; Okur E; Dundar U; Dikici A; Kahveci OK
    Clin Rheumatol; 2014; 33(10):1481-7. PubMed ID: 24770796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis.
    Kang KY; Lee KY; Kwok SK; Ju JH; Park KS; Hong YS; Kim HY; Park SH
    Joint Bone Spine; 2011 Mar; 78(2):188-93. PubMed ID: 20621536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.
    Vis M; Havaardsholm EA; Haugeberg G; Uhlig T; Voskuyl AE; van de Stadt RJ; Dijkmans BA; Woolf AD; Kvien TK; Lems WF
    Ann Rheum Dis; 2006 Nov; 65(11):1495-9. PubMed ID: 16606653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.
    Visvanathan S; van der Heijde D; Deodhar A; Wagner C; Baker DG; Han J; Braun J
    Ann Rheum Dis; 2009 Feb; 68(2):175-82. PubMed ID: 18495735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
    Marzo-Ortega H; McGonagle D; Jarrett S; Haugeberg G; Hensor E; O'connor P; Tan AL; Conaghan PG; Greenstein A; Emery P
    Ann Rheum Dis; 2005 Nov; 64(11):1568-75. PubMed ID: 15829577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Are there any positive effects of TNF-alpha blockers on bone metabolism?].
    Seriolo B; Paolino S; Sulli A; Cutolo M
    Reumatismo; 2006; 58(3):199-205. PubMed ID: 17013436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy.
    Barnabe C; Hanley DA
    Semin Arthritis Rheum; 2009 Oct; 39(2):116-22. PubMed ID: 18585759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
    Wijbrandts CA; Klaasen R; Dijkgraaf MG; Gerlag DM; van Eck-Smit BL; Tak PP
    Ann Rheum Dis; 2009 Mar; 68(3):373-6. PubMed ID: 18408246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral density in patients with rheumatoid arthritis treated with infliximab.
    Vis M; Voskuyl AE; Wolbink GJ; Dijkmans BA; Lems WF;
    Ann Rheum Dis; 2005 Feb; 64(2):336-7. PubMed ID: 15647447
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of tumour necrosis factor α blockade on bone metabolism in chronic inflammatory joint diseases].
    Aguilar Del Rey FJ; García Portales R; Haro Liger M; Rodríguez Andreu J; Casals Sánchez JL; Pérez González R
    Med Clin (Barc); 2016 Jul; 147(2):56-62. PubMed ID: 27209224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Filippatos TD; Vasakos S; Nikas SN; Drosos AA
    J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of biologic antirheumatic treatments on bone metabolism in rheumatoid arthritis and ankylosing spondylitis].
    Głuszko P
    Endokrynol Pol; 2009; 60(2):115-21. PubMed ID: 19396755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
    Lange U; Teichmann J; Müller-Ladner U; Strunk J
    Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis.
    Kang KY; Ju JH; Park SH; Kim HY
    Rheumatology (Oxford); 2013 Apr; 52(4):718-26. PubMed ID: 23275389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Vasakos S; Nikas SN; Drosos AA
    Ann Rheum Dis; 2005 May; 64(5):765-6. PubMed ID: 15458960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour necrosis factor blockade and the risk of osteoporosis: back to the future.
    Sambrook P
    Arthritis Res Ther; 2007; 9(4):107. PubMed ID: 17850677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study.
    van der Weijden MA; van Denderen JC; Lems WF; Nurmohamed MT; Dijkmans BA; van der Horst-Bruinsma IE
    J Rheumatol; 2016 Apr; 43(4):758-64. PubMed ID: 26879348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.